{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:55:58Z","timestamp":1792061758529,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MRF-131-0006-RG-KHOS-C0942"],"award-info":[{"award-number":["MRF-131-0006-RG-KHOS-C0942"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y503216\/1"],"award-info":[{"award-number":["MR\/Y503216\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Africa"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lanafr.2026.100061","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:03:03Z","timestamp":1779148983000},"page":"100061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment outcomes and post-treatment mortality among people with multidrug\/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7386-6553","authenticated-orcid":false,"given":"Faye","family":"Greenwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-8752","authenticated-orcid":false,"given":"Rashidatu Fouad","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousman","family":"Conteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-2367","authenticated-orcid":false,"given":"Matthew J","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wingfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanafr.2026.100061_bib1","series-title":"Global Tuberculosis Report 2025","year":"2025"},{"issue":"10","key":"10.1016\/j.lanafr.2026.100061_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.lanafr.2026.100061_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMc2404644","article-title":"Transmission as a key driver of resistance to the new tuberculosis drugs","volume":"392","author":"Goig","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100061_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.lanafr.2026.100061_bib5","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1016\/S2214-109X(23)00369-8","article-title":"Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis","volume":"11","author":"Portnoy","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"7","key":"10.1016\/j.lanafr.2026.100061_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001675","article-title":"Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru","volume":"11","author":"Wingfield","year":"2014","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.lanafr.2026.100061_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaf206","article-title":"Long-term mortality trends among individuals with tuberculosis: a retrospective cohort study of individuals diagnosed with tuberculosis in Brazil","volume":"82","author":"Kim","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.lanafr.2026.100061_bib8","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1093\/cid\/ciaf363","article-title":"Long-term outcomes among people with multi-drug resistant tuberculosis in Vietnam: a prospective cohort study","volume":"81","author":"MacLean","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.lanafr.2026.100061_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1473-3099(19)30309-3","article-title":"Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis","volume":"19","author":"Romanowski","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.lanafr.2026.100061_bib10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S2213-2600(24)00429-6","article-title":"Post-tuberculosis lung disease: towards prevention, diagnosis, and care","volume":"13","author":"Meghji","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100061_bib11","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2214-109X(22)00004-3","article-title":"Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study","volume":"10","author":"Kamara","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanafr.2026.100061_bib12","series-title":"National Treatment Guidelines for the Management of Drug-Resistant Tuberculosis in Sierra Leone","year":"2016"},{"key":"10.1016\/j.lanafr.2026.100061_bib13","series-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","year":"2019"},{"issue":"2","key":"10.1016\/j.lanafr.2026.100061_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"Linh","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100061_bib15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/ije\/30.4.668","article-title":"Theories for social epidemiology in the 21st century: an ecosocial perspective","volume":"30","author":"Krieger","year":"2001","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.lanafr.2026.100061_bib16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ije\/dyaa213","article-title":"Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations","volume":"50","author":"Tennant","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100061_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.lanafr.2026.100061_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2025-001375","article-title":"Factors associated with: problems of using exploratory multivariable regression to identify causal risk factors","volume":"4","author":"Lewer","year":"2025","journal-title":"BMJ Med"},{"issue":"7139","key":"10.1016\/j.lanafr.2026.100061_bib19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Bonferroni adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.lanafr.2026.100061_bib20","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment and Care","year":"2025"},{"issue":"2","key":"10.1016\/j.lanafr.2026.100061_bib21","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2214-109X(24)00467-4","article-title":"24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation","volume":"13","author":"Sweeney","year":"2025","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.lanafr.2026.100061_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanafr.2026.100061_bib23","article-title":"BEAT tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis","author":"Conradie","year":"2025","journal-title":"medRxiv"},{"issue":"5","key":"10.1016\/j.lanafr.2026.100061_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampicin-resistant, foluroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanafr.2026.100061_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1983","article-title":"Priorities in addressing rifampicin resistant TB","volume":"391","author":"Yates","year":"2025","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.lanafr.2026.100061_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2471\/BLT.13.124800","article-title":"Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis","volume":"92","author":"MacPherson","year":"2014","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.lanafr.2026.100061_bib27","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S2214-109X(23)00544-2","article-title":"Beyond tuberculosis: a person-centred and rights-based approach to screening for household contacts","volume":"12","author":"Calderwood","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.lanafr.2026.100061_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40249-025-01324-6","article-title":"The social determinants of tuberculosis: a case-control study characterising pathways to equitable intervention in Peru","volume":"14","author":"Saunders","year":"2025","journal-title":"Infect Dis Poverty"},{"issue":"4","key":"10.1016\/j.lanafr.2026.100061_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(15)00434-X","article-title":"Fighting poverty to prevent tuberculosis","volume":"16","author":"Saunders","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanafr.2026.100061_bib31","series-title":"Guidance on Social Protection for People Affected by Tuberculosis","year":"2024"},{"key":"10.1016\/j.lanafr.2026.100061_bib32","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 6: Tuberculosis and Comorbidities","year":"2025"},{"issue":"8","key":"10.1016\/j.lanafr.2026.100061_bib33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1159\/000512531","article-title":"Post-tuberculosis lung disease: clinical review of an under-recognised global challenge","volume":"100","author":"Allwood","year":"2021","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.lanafr.2026.100061_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12890-018-0777-3","article-title":"TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB \u2013 a study protocol","volume":"19","author":"Rachow","year":"2019","journal-title":"BMC Pulm Med"}],"container-title":["The Lancet Regional Health - Africa"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050501126000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050501126000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:36:34Z","timestamp":1792060594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050501126000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S3050501126000428"],"URL":"https:\/\/doi.org\/10.1016\/j.lanafr.2026.100061","relation":{},"ISSN":["3050-5011"],"issn-type":[{"value":"3050-5011","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes and post-treatment mortality among people with multidrug\/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Africa","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanafr.2026.100061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100061"}}